Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Neural epidermal growth factor-like protein 2 (NELL2) is a secreted, multimodular glycoprotein highly expressed in neural tissue and involved in critical aspects of neuronal development, such as polarization, axon elongation, branching, and synaptic remodeling[1][2][3]. The protein contains von Willebrand factor C domains, a thrombospondin-1-like domain, and multiple EGF-like repeats, and it acts both extracellularly—by binding to the Roundabout (Robo) family of axon guidance receptors—and intracellularly by modulating PKC and ERK signaling pathways[1][4]. NELL2 expression is necessary for proper neuronal differentiation and axon morphogenesis, and alterations in its expression or activity have been linked to cancer, neurodevelopmental disorders, and may serve as diagnostic or prognostic biomarkers in select neurological conditions[3][2]. No drugs currently target NELL2 directly, and its function as a ligand, not a classical receptor, means therapeutic targeting is still experimental.
Binds as a ligand to Robo2 and Robo3 receptor proteins (Roundabout family) Modulates ERK and PKC signaling pathways intra- and extracellularly
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Neural epidermal growth factor-like protein 2 (NELL2).